Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Laguno, Montserrat; Wichmann, Miguel Ángel von; Eynde, Eva Van den; Navarro, Jordi; Cifuentes, Carmen; Murillas, Javier; Veloso, Sergi; Martı́nez-Rebollar, Marı́a; Guardiola, Josep M.; Jou, Antoni; Gómez-Sirvent, J.L.; Cervantes, Manel; Pineda, Juan A.; López‐Calvo, Soledad; Carrero, Ana; Montes, Marisa; Deig, Elisabet; Tapiz, A.; Ruiz-Mesa, Juan D.; Cruceta, Anna; Lazzari, Elisa de; Mallolas, Josép

doi:10.1016/j.ijid.2016.10.028

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, telaprevir (an inhibitor of the HCV NS3/4 protease) in combination with PegIFN-␣/ribavirin can be effective in treating chronic HCV patients who are unresponsive to conventional PegIFN-␣/ribavirin therapy (55). Several other HCV NS3/4A protease inhibitors used in combination with PegIFN-␣ and ribavirin may also achieve improved rates of a sustained virological response (56)(57)(58)(59). However, the toxicity when they are combined with PegIFN-␣ and ribavirin still limits their overall efficacy (60,61).…”

Section: Fda-approved Host-directed Antiviral Agentsmentioning

confidence: 99%

Host-Directed Antiviral Therapy

et al. 2020

View full text Add to dashboard Cite

SUMMARY Antiviral drugs have traditionally been developed by directly targeting essential viral components. However, this strategy often fails due to the rapid generation of drug-resistant viruses. Recent genome-wide approaches, such as those employing small interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats (CRISPR) or those using small molecule chemical inhibitors targeting the cellular “kinome,” have been used successfully to identify cellular factors that can support virus replication. Since some of these cellular factors are critical for virus replication, but are dispensable for the host, they can serve as novel targets for antiviral drug development. In addition, potentiation of immune responses, regulation of cytokine storms, and modulation of epigenetic changes upon virus infections are also feasible approaches to control infections. Because it is less likely that viruses will mutate to replace missing cellular functions, the chance of generating drug-resistant mutants with host-targeted inhibitor approaches is minimized. However, drug resistance against some host-directed agents can, in fact, occur under certain circumstances, such as long-term selection pressure of a host-directed antiviral agent that can allow the virus the opportunity to adapt to use an alternate host factor or to alter its affinity toward the target that confers resistance. This review describes novel approaches for antiviral drug development with a focus on host-directed therapies and the potential mechanisms that may account for the acquisition of antiviral drug resistance against host-directed agents.

show abstract

Section: Fda-approved Host-directed Antiviral Agentsmentioning

confidence: 99%

Host-Directed Antiviral Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interessante observar que na época o alcance da RVS com IFN reduziu muito a incidência de carcinoma hepatocelular. No entanto, sua eficácia e segurança não eram satisfatórias além de falhas no tratamento e pacientes que não o toleravam bem 14,33 .…”

Section: Tratamento Até 2011unclassified

Hepatite C

Perlin

Groto

Perlin

et al. 2019

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

O objetivo deste trabalho foi realizar uma revisão da literatura sobre os fármacos utilizados para o tratamento da hepatite C desde a descoberta do vírus, em 1989. Para atingir esse objetivo, foi realizada uma pesquisa nas bases Medline e SciELO, utilizando o termos “hepatite C”, “tratamento”, “livre de interferon”, “revisão” e “ensaio clínico”. Este trabalho apresenta uma revisão das características gerais da hepatite C juntamente com sua epidemiologia e diagnóstico. Durante muito tempo, a única opção disponível para o tratamento da hepatite C foi o interferon. Esta droga não mostrou boa eficácia e seu uso foi minimizado com o surgimento de novos regimes sem interferon que aumentaram a taxa de sucesso para algo em torno de 95%. Tais medicamentos permitiram o alcance real da cura do vírus, embora estejam disponíveis no Sistema Único de Saúde (SUS) brasileiro, são tratamentos caros que restringem o acesso a grande parte da população infectada.

show abstract

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Cited by 2 publications

References 27 publications

Host-Directed Antiviral Therapy

Host-Directed Antiviral Therapy

Hepatite C

Contact Info

Product

Resources

About